Fate Therapeutics (NASDAQ:FATE) announced management participation in several third quarter 2026 investor conferences focused on healthcare and therapeutics.
Events include forums hosted by Leerink Partners, Wells Fargo, Cantor Fitzgerald, and H.C. Wainwright, with potential presentations or fireside chats and webcasts available through the company’s investor relations website.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – FATE
-3.31%
35 alerts
-3.31%Session close to close
+13.7%Peak in 24 hr 23 min
$373.57MMarket Cap
1.1xRel. Volume
In the Jul 2 session, FATE declined 3.31%, reflecting a moderate negative market reaction.
Argus tracked a peak move of +13.7% during that session.
Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility.
This announcement expands FATE’s visibility via multiple Q3 investor conferences, offering updates o...
Analysis
This announcement expands FATE’s visibility via multiple Q3 investor conferences, offering updates on its iPSC-derived pipeline. Prior mixed price responses to news and recent insider selling highlight execution and sentiment as key factors to monitor.
Key Figures
Conference quarter:Q3 2026Leerink forum dates:July 14–15, 2026Wells Fargo conference:21st Annual+5 more
8 metrics
Conference quarterQ3 2026Timing of listed investor conferences
Leerink forum datesJuly 14–15, 2026Leerink Partners Therapeutics Forum in Boston, MA
"transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies"
Cells taken from an adult (such as skin or blood) that scientists ‘reprogram’ so they behave like versatile early-stage cells capable of becoming many different cell types in the body. For investors, these cells matter because they enable development of personalized therapies, safer and faster drug testing, and potential regenerative treatments—like resetting a gadget to factory mode so it can run many different apps—creating new commercial opportunities and affecting biotech valuation and risk.
ipsc-derivedmedical
"transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies"
Cells labeled “iPSC-derived” started as ordinary adult cells that scientists rewound into a flexible, stem-cell state and then nudged to become a specific cell type (for example heart, nerve, or liver cells). For investors, this flags a technology platform used in drug development, disease modeling, and regenerative therapies — like turning one tool into many — which can offer scalable new products but also carries clinical, manufacturing and regulatory risk.
cellular immunotherapiesmedical
"iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases"
Cellular immunotherapies are medical treatments that use living immune cells, taken from a patient or donor and then trained, modified, or expanded in a lab so they better recognize and attack disease, such as cancer or infection. For investors, these therapies matter because they can offer dramatic, durable patient responses and premium pricing but also carry high development, manufacturing and regulatory risks—think of them as highly trained sniffer dogs that can be powerful but expensive and complex to deploy.
webcasttechnical
"a live webcast will be accessible under “Events & Presentations” in the Investors section"
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the third quarter of 2026.
Leerink Partners Therapeutics Forum
Location: Boston, MA
Date: July 14th & 15th
Wells Fargo 21st Annual Healthcare Conference
Location: Boston, MA
Date: September 8th – 10th
12th Annual Cantor Fitzgerald Global Healthcare Conference
Location: New York, NY
Date: September 9th – 11th
H.C. Wainwright 28th Annual Global Investment Conference
Location: New York, NY
Date: September 14th – 16th
The Company may participate in a presentation or a fireside chat at these conferences. When available, a live webcast will be accessible under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. An archived replay of the webcast will be available for 30 days on the Company’s website following the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Which investor conferences will Fate Therapeutics (NASDAQ:FATE) attend in Q3 2026?
Fate Therapeutics plans to attend investor conferences hosted by Leerink Partners, Wells Fargo, Cantor Fitzgerald, and H.C. Wainwright in Q3 2026. These events are leading healthcare and therapeutics forums in Boston and New York, targeting institutional investors and healthcare specialists.
When is Fate Therapeutics presenting at the Leerink Partners Therapeutics Forum 2026?
Fate Therapeutics will participate in the Leerink Partners Therapeutics Forum in Boston on July 14 and 15, 2026. According to the company, management may join a presentation or fireside chat, with webcast access planned through its investor relations website when available.
What are the dates of Fate Therapeutics at the Wells Fargo 21st Annual Healthcare Conference 2026?
Fate Therapeutics is scheduled for the Wells Fargo 21st Annual Healthcare Conference in Boston from September 8 to 10, 2026. According to the company, management may engage in investor discussions and a webcast is expected for remote participants via the investor website.
How can investors watch Fate Therapeutics at the 12th Annual Cantor Fitzgerald Global Healthcare Conference?
Investors can access Fate Therapeutics’ participation in the Cantor Fitzgerald Global Healthcare Conference, held in New York from September 9 to 11, 2026, via live webcast. According to the company, the stream will appear under “Events & Presentations” on its investor website.
Will Fate Therapeutics webcast its appearance at the H.C. Wainwright 28th Annual Global Investment Conference?
Fate Therapeutics expects to webcast its participation at the H.C. Wainwright 28th Annual Global Investment Conference in New York, September 14 to 16, 2026. According to the company, live access and a 30-day archived replay will be available on its investor relations webpage.
Where can I find Fate Therapeutics conference webcasts and replays in 2026?
Conference webcasts and 30-day archived replays for Fate Therapeutics will be available under “Events & Presentations” in the Investors section of www.fatetherapeutics.com. According to the company, links will be posted once specific conference schedules and formats are finalized.
